Table 3.

Antibodies to AAV2 in rats and monkeys after administration with rAAV2/human TNFR:Fc.

		Rat				Monkey
Group	Dilution of sera	Day7	Day29	Day71	Day99	Day8	Day36	Day64	Day99	Day134
PBS control	1:50	0/6	0/6	0/6	0/6	0/8	0/4	0/4	0/4	0/2
Low-dose		0/6	6/6	5/6	1/6	0/8	0/4	0/4	0/4	0/2
High-dose		0/6	6/6	5/6	1/6	0/8	0/4	0/4	0/4	0/2
PBS control	1:200	0/6	0/6	0/6	0/6	0/8	0/4	0/4	0/4	0/2
Low-dose		0/6	2/6	1/6	0/6	0/8	0/4	0/4	0/4	0/2
High-dose		0/6	4/6	1/6	0/6	0/8	0/4	0/4	0/4	0/2
PBS control	1:800	0/6	0/6	0/6	0/6	0/8	0/4	0/4	0/4	0/2
Low-dose		0/6	0/6	0/6	0/6	0/8	0/4	0/4	0/4	0/2
High-dose		0/6	0/6	0/6	0/6	0/8	0/4	0/4	0/4	0/2

Notes: Low- and high- dose group presents the animal were treated repeatedly with the 1×10¹² vg/mL and 3×10¹² vg/mL rAAV2/human TNFR:Fc, respectively.